A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa
Clinical Trial Grant
Administered By
Dermatology
Awarded By
UCB Pharma, Inc.
Start Date
July 15, 2020
End Date
March 30, 2023
Administered By
Dermatology
Awarded By
UCB Pharma, Inc.
Start Date
July 15, 2020
End Date
March 30, 2023